The path to approved Alzheimer’s treatments starts with a better way to diagnose patients. Bill Gates and ADDF co-founder Leonard Lauder are partnering and adopting a new approach that brings together philanthropic capital with a venture mindset to advance bold new ideas for easier and more accurate diagnosis of Alzheimer’s disease and related dementias.
Currently available tests for Alzheimer’s are expensive and invasive. Reliable, affordable, and accessible biomarkers have the potential to revolutionize how we approach Alzheimer’s disease by allowing us to better understand how the disease progresses, more easily identify people for clinical trials, and more accurately monitor their response to treatments.
Diagnostics Accelerator brings together initial commitments totaling more than $30 million from partners including Bill Gates, Leonard Lauder, the Dolby family, the Charles and Helen Schwab Foundation, and others, who are committed to bringing the funding, focus, resources, and urgency required to solve this important problem.
This call-to-action challenges the research community to develop cutting-edge biomarkers and explore novel diagnostic technologies that would reduce the impact of this devastating disease.
Funding is open to researchers and clinicians worldwide at:
Academic medical centers and universities or nonprofits
Industry partnerships are strongly encouraged.
Funding is provided through mission-related investments that require return on investment. Existing companies and new spinouts are both eligible.